{"id":"inactivated-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated (killed) influenza virus particles or recombinant viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, B cells produce neutralizing antibodies against viral surface proteins (hemagglutinin and neuraminidase), while T cells develop memory to recognize infected cells, providing protection against subsequent natural infection with matching or similar viral strains.","oneSentence":"The inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains without causing infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:56.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults and children"}]},"trialDetails":[{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT06560151","phase":"PHASE2","title":"Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-08-21","conditions":"Influenza","enrollment":1380},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT01024400","phase":"PHASE2","title":"Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Influenza","enrollment":110},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT03816878","phase":"PHASE1","title":"Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-08","conditions":"Influenza","enrollment":32},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT07177417","phase":"PHASE4","title":"Characterizing the Human Airway Immune Response to FluMist Vaccination","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-09-09","conditions":"Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response","enrollment":30},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT06842173","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2025-09-01","conditions":"Avian Influenza A Virus","enrollment":700},{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06907667","phase":"NA","title":"Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-03","conditions":"Vaccination; Infection","enrollment":735},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT02783170","phase":"PHASE4","title":"Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-09","conditions":"Pregnancy","enrollment":81},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT00417560","phase":"NA","title":"Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2007-01","conditions":"Influenza","enrollment":""},{"nctId":"NCT05027932","phase":"PHASE1","title":"Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-06-27","conditions":"Influenza","enrollment":45},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT01997450","phase":"","title":"A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age","status":"TERMINATED","sponsor":"MedImmune LLC","startDate":"2013-12-02","conditions":"Influenza Vaccine Effectiveness","enrollment":4121},{"nctId":"NCT03898986","phase":"PHASE1","title":"The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-10-08","conditions":"Influenza","enrollment":18},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03888989","phase":"PHASE1","title":"Response to Influenza Vaccine During Pregnancy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-09-30","conditions":"Influenza","enrollment":2},{"nctId":"NCT06827873","phase":"NA","title":"Effect of Oral Supplements for Influenza Vaccine Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2025-02","conditions":"Influenza Vaccine Response","enrollment":45},{"nctId":"NCT05028634","phase":"PHASE3","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-11-11","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT03753347","phase":"PHASE4","title":"TITRE III: Influenza B Immunogenicity Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Centre for Disease Control","startDate":"2018-12-01","conditions":"Influenza","enrollment":55},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT03165981","phase":"PHASE4","title":"Fever After Simultaneous Versus Sequential Vaccination in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-25","conditions":"Fever After Vaccination, Fever, Febrile Seizure","enrollment":221},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT03369808","phase":"PHASE1, PHASE2","title":"A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2017-12-29","conditions":"H7N9 Influenza","enrollment":360},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT02921997","phase":"PHASE2","title":"H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-07","conditions":"Avian Influenza, H1N1 Influenza, Influenza","enrollment":30},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT04667117","phase":"PHASE4","title":"A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-14","conditions":"Relapsing Multiple Sclerosis","enrollment":63},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT03014310","phase":"PHASE1","title":"H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-09","conditions":"Avian Influenza","enrollment":388},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT03312231","phase":"PHASE2","title":"Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-14","conditions":"Avian Influenza, Influenza Immunisation","enrollment":720},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT00630331","phase":"PHASE3","title":"Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-10","conditions":"Influenza","enrollment":11404},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824},{"nctId":"NCT04998344","phase":"PHASE4","title":"An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bergen","startDate":"2021-04-07","conditions":"Influenza Viral Infections","enrollment":3800}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"RESPIRATORY FAILURE"},{"count":4,"reaction":"RHABDOMYOLYSIS"},{"count":3,"reaction":"COORDINATION ABNORMAL"},{"count":3,"reaction":"DIABETIC NEUROPATHY"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"GUILLAIN-BARRE SYNDROME"},{"count":3,"reaction":"INFECTION"},{"count":3,"reaction":"LEUKOCYTOSIS"},{"count":3,"reaction":"MOBILITY DECREASED"},{"count":3,"reaction":"PAIN"}],"_approvalHistory":[],"publicationCount":1532,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IIV","FLUARIX","VAXIGRIP®, Sanofi Pasteur","Fluzone","Vaxigrip, Shenzhen Aventis Pasteur Biological"],"phase":"marketed","status":"active","brandName":"Inactivated Influenza Vaccine","genericName":"Inactivated Influenza Vaccine","companyName":"St. Louis University","companyId":"st-louis-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"The inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains without causing infection. Used for Prevention of seasonal influenza in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}